Acute Lung Inflammation (ALI) and Acute Respiratory Distress Syndrome (ARDS) initiate and propagate lung injury through a plethora of mechanisms which until today, after more than 35 years of research, still aren’t fully understood. And while human studies have provided scientists with critical descriptive data on the development and pathophysiology of inflammatory processes in the lungs, the need for animal models to understand the mechanism of injury at the biochemical level grows only more relevant as time passes. 

At PharmaLegacy, we understand the ever-growing need for state-of-the-art animal models in ALI and ARDS. With our Lipopolysaccharide-induced ALI models in mice, rats and monkeys, we are committed to providing you with everything you need to take your preclinical studies all the way to the finish line.